CytomX Therapeutics to Present at Upcoming November Investor Conferences
2022年11月3日 - 5:15AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated oncology therapeutics, today announced that
Sean McCarthy, D.Phil., chief executive officer and chairman, will
participate in the following investor conferences in November.
BMO Biopharma Spotlight Series: Oncology
DayDate: Wednesday, November 9, 2022Fireside Chat: 11:30
a.m. ETLocation: Virtual
Piper Sandler 34th
Annual Healthcare ConferenceDate: Tuesday,
November 29, 2022Fireside Chat: 8:30 a.m. ETLocation: New York,
NY
A live webcast of the Piper Sandler fireside chat will be
available on the Events and Presentations page of CytomX’s website
at www.cytomx.com. In addition, management will be available for
one-on-one meetings with investors who are registered to attend the
conferences.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
dedicated to destroying cancer differently. By pioneering a novel
class of conditionally activated biologics, powered by its Probody®
technology platform, CytomX’s goal is to transcend the limits of
current cancer treatments. CytomX’s robust and differentiated
pipeline comprises seven therapeutic candidates across multiple
treatment modalities including antibody-drug conjugates (“ADCs”),
T-cell engaging bispecific antibodies (“TCBs”), and immune
modulators such as cytokines and checkpoint inhibitors (“CPIs”).
CX-2029 is an investigational conditionally activated antibody-drug
conjugate (ADC) directed toward CD71, which has demonstrated
encouraging antitumor activity in patients with squamous non-small
cell lung cancer and is being developed in collaboration with
AbbVie. CytomX’s clinical pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb, as well as CX-904, a
conditionally activated T-cell-engaging bispecific antibody
targeting the epidermal growth factor receptor (EGFR) on tumor
cells and the CD3 receptor on T cells, which is partnered with
Amgen. In addition, CytomX has a diverse preclinical portfolio of
wholly-owned assets including CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. Praluzatamab ravtansine is an
investigational conditionally activated ADC directed toward CD166
that demonstrated single agent clinical activity in a Phase 2 study
for patients with advanced HR+/HER2-non-amplified breast cancer.
Following the Phase 2 results, CytomX decided not to further
progress praluzatamab ravtansine alone and is seeking a partner to
further develop the molecule. CytomX has also established strategic
collaborations with multiple leaders in oncology, including AbbVie,
Amgen, Astellas, and Bristol Myers Squibb. For more information
about CytomX and how it is working to make conditionally activated
treatments the new standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024